Summary of HR 2214 - DRUG Act

Bill Overview

Bill Number: HR 2214

Title: DRUG Act

Status: Introduced in House

Introduced Date: March 18, 2025

Classification: Bill

The DRUG Act aims to address critical issues related to drug pricing, access, and regulation in the United States. The bill seeks to implement measures that enhance transparency in drug pricing, improve access to affordable medications, and promote competition within the pharmaceutical industry.

Key Provisions

While the full text of the bill has not been provided, the following key provisions are anticipated based on the bill's title and legislative intent:

• Transparency in Drug Pricing: The bill may require pharmaceutical companies to disclose pricing information, including the costs of research and development, production, and marketing of drugs.

• Access to Medications: Provisions may be included to ensure that essential medications are available at lower costs to consumers, potentially through price caps or negotiated pricing strategies.

• Promotion of Generic Drugs: The bill could encourage the development and approval of generic medications to foster competition and reduce prices for consumers.

• Regulatory Reforms: Changes to the regulatory framework governing drug approvals and market entry may be proposed to streamline processes and enhance efficiency.

Affected Parties

The DRUG Act is expected to impact a wide range of stakeholders, including:

• Consumers: Individuals who rely on prescription medications may benefit from lower prices and improved access to necessary drugs.

• Pharmaceutical Companies: The bill may impose new requirements on drug manufacturers regarding pricing transparency and competition, potentially affecting their profit margins.

• Healthcare Providers: Doctors and healthcare professionals may see changes in the availability of medications and pricing structures, influencing treatment options for patients.

• Insurance Companies: Insurers may need to adjust their coverage policies and pricing strategies in response to the changes proposed in the bill.

Legislative Process

• Committee Referrals: Upon introduction, HR 2214 was referred to the following committees for consideration:
  • Committee on Energy and Commerce
  • Committee on Ways and Means
  • Committee on Education and Workforce

The Speaker of the House will determine the timeline for consideration by these committees. This multi-committee referral indicates the bill's broad implications across various sectors of healthcare and economics.

Sponsors

The bill is sponsored by Mariannette Miller-Meeks and has several cosponsors, including:
- Rick W. Allen
- Nanette Diaz Barragán
- Bradley Scott Schneider
- Donald Norcross
- Nicole Malliotakis

Conclusion

The DRUG Act represents a significant legislative effort to reform drug pricing and access in the United States. As the bill progresses through the legislative process, further details will emerge regarding its specific provisions and potential impacts on the healthcare landscape. Stakeholders are encouraged to monitor developments closely as the bill moves through committee review and potential amendments.